Blocking key protein triggers cancer cell self-destruction

(Press-News.org) NYU Langone Health researchers found that a type of cell death caused by a buildup of highly reactive molecules suppresses lung tumor growth.

The process, called ferroptosis, evolved to let the body signal for self-destruction of cells that are overly stressed for various reasons. This includes cancer cells, but they in turn evolved to have mechanisms that counter ferroptosis so they can continue their uncontrolled growth despite the stress it creates.

Published online November 5 in Nature, the new study showed that an experimental treatment  blocked the action in cancer cells of a protein called ferroptosis suppressor protein 1 (FSP1) to reduce by up to 80% tumor growth in mice with lung adenocarcinoma (LUAD). Lung cancer is the leading cause of cancer death worldwide, with LUAD the most common lung cancer among nonsmokers, making up about 40% of cases.

“This first test of a drug that blocks ferroptosis suppression highlights the importance of the process to cancer cell survival and paves the way for a new treatment strategy,” said senior study author Thales Papagiannakopoulos, PhD[GW1] , an associate professor in the Department of Pathology[GW2]  at the NYU Grossman School of Medicine.

Harmful Reactions

Ferroptosis kills cells by building up levels of iron, which generates highly reactive molecules formed from oxygen, water, and hydrogen peroxide called reactive oxygen species (ROS). Important for normal cell signaling, ROS also often cause oxidative stress, a disease mechanism in which ROS oxidize (add oxygen molecules to) delicate proteins and DNA to pull them apart. ROS damage fats making up the outer layers of cells to cause cell death and tissue damage.

For the new study, the research team genetically engineered mice to delete the FSP1 gene in lung cancer cells, which led to increased cancer cell death and significantly smaller tumors. The team also found that a potent, relatively new drug type, an FSP1 inhibitor called icFSP1, improved overall survival of lung tumor-bearing mice, nearly to the extent seen in mice with lung tumors genetically engineered to lack the FSP1 gene.

Their work also showed that Fsp1 is likely a better target for future drugs than another ferroptosis suppressor, glutathione peroxidase 4 (GPX4), which has been studied longer.  FSP1 was shown in the new study to play a greater role in blocking ferroptosis in lung cancer cells specifically, and a smaller role than GPX4 in normal cell functions (likely fewer side effects). Unlike with GPX4, increased FSP1 levels were also found to track with poorer survival in human LUAD patients.

"Our future research will focus on optimizing FSP1 inhibitors and investigating the potential of harnessing ferroptosis as a treatment strategy for other solid tumors, such as pancreatic cancer," said lead study author Katherine Wu, an MD/PhD student working in the Papagiannakopoulos lab. "We aim to translate these findings from the lab into novel clinical therapies for cancer patients.”

***

Along with Wu and Pagagiannakopoulos, study authors from the Department of Pathology at NYU Langone are co-first author Alec Vaughan, Jozef Bossowski, Yuan Hao, Aikaterini Ziogou, Mari Nakamura, Ray Pillai, Mariana Mancini, Sahith Rajalingam, and Suckwoo Chung.  Also study authors are Seon Min Kim, Tae Ha Kim, and Yun Pyo Kang of the College of Pharmacy and Research Institute of Pharmaceutical Sciences at Seoul National University; Mingqi Han and David Shackelford in the Department of Pulmonary and Critical Care Medicine at the David Geffen School of Medicine, University of California Los Angeles; Toshitaka Nakamura and Marcus Conrad from the Institute of Metabolism and Cell Death, Molecular Targets and Therapeutics Center, at Helmholtz Munich in Germany, and Lidong Wang and Diane Simeone from the Moores Cancer Center, University of California, San Diego, La Jolla.

The study was funded by National Institutes of Health grants S10RR027926, S10OD032292, R37CA222504, R01CA227649, R01CA283049, R01CA262562, T32GM136542, T32GM136573, and T32GM136542. Also providing support for the work were American Cancer Society Research Scholar Grant (RSG-17-20001–TBE), Ruth L. Kirschstein Individual Predoctoral National Research Service Award fellowship (F30CA275258), Deutsche Forschungsgemeinschaft (DFG) (CO 291/7-1 Priority Program SPP 2306 [CO 291/9-1, #461385412; CO 291/10-1, #461507177], the European Research Council under the European Union’s Horizon 2020 research and innovation program (grant GA 884754), and Perlmutter Cancer Center Support Grant P30CA016087.

Papagiannakopoulos received funding from the Pfizer Medical Education Group, Dracen Pharmaceuticals, Kymera Therapeutics, Bristol Myers Squibb, and Agios available under an aCC-BY-NC-ND 4.0 international license. The relationships are being managed in accordance with NYU Langone Health policies. 

About NYU Langone Health

NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient, Inc., has ranked NYU Langone No. 1 out of 118 comprehensive academic medical centers across the nation for four years in a row, and U.S. News & World Report recently ranked four of its clinical specialties No. 1 in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. The system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.

END